¹Ì±¹ 1Â÷Áغñ¹Ý °­ÀǽÇ
Insurance¿Í ¾à»ç¹ý - Key Points 2010.02.20
Public relations: Á¶Á÷°ú °øÁß(Public)°úÀÇ °ü°è¸¦ Çü¼ºÇÏ´Â °ÍÀ» PRÀ̶ó°í ÇÏ¸ç ½±°Ô´Â È«º¸¸¦ »ý°¢ÇÏ¸é µÈ´Ù. ¿¹µé: 1. Corporations use marketing public relations (MPR) to convey information about the products they manufacture or services th...
Biotechnology - Key Points 2010.02.20
1. Omalizumab (OMZ) is a recombinant, humanized monoclonal anti-IgE antibody. It inhibits the immune system¡¯s response to allergens in a dose-dependent manner, by binding to free IgE and resulting in ...
Microbiology - Key Points 2010.02.20
1. Methicillin-sensitive staphylococciÀÇ DOC´Â? Cefazolin 2. General population¿¡¼­ methicillin-resistant S. aureusÀÇ carrigae rateÀº? 25-50% 3. Methicillin-resistant S. aureusÀÇ risk factor°¡ ¾Æ´Ñ °ÍÀº? a. in...
¾à»ç¹ý, ¾à±¹ practice - Key Points 2010.02.20
Prescribing Authority 2010.02.20
    ¹Ì±¹ 2Â÷Áغñ¹Ý °­ÀǽÇ
24ÁÖ: Gout and Others ½Ç½Ã°£ °­ÀÇ Recording 2009.12.14
2009/5/9 ½Ç½Ã°£ °­ÀÇ ³ìÈ­ºÐÀÔ´Ï´Ù. °­ÀÇ ¹üÀ§´Â APhA Review Chapter 22 Gout°ú °­ÀÇ¿¡¼­ ´Ù·çÁö ¾ÊÀº ´Ù¸¥ ÁúȯµéÀÔ´Ï´Ù. ¿©±â¸¦ Ŭ¸¯ÇÏ½Ã¸é °­ÀǸ¦ ½ÃûÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù. À§ÀÇ pdf ÆÄÀÏÀ» ´Ù¿î·Îµå¹Þ¾Æ¼­ ÀμâÇϽŠ´ÙÀ½, Çʱ⿡ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
23ÁÖ: Dementia ½Ç½Ã°£ °­ÀÇ Recording 2009.12.14
2009/5/7 ½Ç½Ã°£ °­ÀÇ ³ìÈ­ºÐÀÔ´Ï´Ù. °­ÀÇ ¹üÀ§´Â APhA Review Chapter 34 Geriatrics and Gerontology (Alzheimer's Disease)ÀÔ´Ï´Ù. ¿©±â¸¦ Ŭ¸¯ÇÏ½Ã¸é °­ÀǸ¦ ½ÃûÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù. À§ÀÇ pdf ÆÄÀÏÀ» ´Ù¿î·Îµå¹Þ¾Æ¼­ ÀμâÇϽŠ´ÙÀ½, Çʱ⿡ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
22ÁÖ: Top 200 Drugs part 12 ½Ç½Ã°£ °­ÀÇ Recording 2009.12.14
2009/5/4 ½Ç½Ã°£ °­ÀÇ ³ìÈ­ºÐÀÔ´Ï´Ù. °­ÀÇ ¹üÀ§´Â Top 200 Drugs part 12ÀÔ´Ï´Ù. ¿©±â¸¦ Ŭ¸¯ÇÏ½Ã¸é °­ÀǸ¦ ½ÃûÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù. À§ÀÇ pdf ÆÄÀÏÀ» ´Ù¿î·Îµå¹Þ¾Æ¼­ ÀμâÇϽŠ´ÙÀ½, Çʱ⿡ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
22ÁÖ: Top 200 Drugs part 11 ½Ç½Ã°£ °­ÀÇ Recording 2009.12.14
21ÁÖ: Top 200 Drugs part 10 ½Ç½Ã°£ °­ÀÇ Recording 2009.12.14
    ¹Ì±¹ 1Â÷Áغñ¹Ý Q&A
[´äº¯] Áú¹® (¿¹Àü ¸ðÀǰí»ç ¹®Á¦)
Áú¹® (¿¹Àü ¸ðÀǰí»ç ¹®Á¦) + 1
[´äº¯] ¸¶³­¹®Á¦Áý Áú¹® (¸¶Áö¸·)
¸¶³­¹®Á¦Áý Áú¹® (¸¶Áö¸·)
[´äº¯] Âа­ÀÇ Áú¹® (¹Ì»ý¹° ¿äÁ¡ ¹× ¹®Á¦µé) + 1
[´äº¯] ¸¶³­¹®Á¦Áý Áú¹® °è¼Ó + 1
Âа­ÀÇ Áú¹® (¹Ì»ý¹° ¿äÁ¡ ¹× ¹®Á¦µé)
¸¶³­¹®Á¦Áý Áú¹® °è¼Ó
[´äº¯] ¸¶³­¹®Á¦Áý Áú¹® Ãß°¡
¸¶³­¹®Á¦Áý Áú¹® Ãß°¡
    ¹Ì±¹ 2Â÷Áغñ¹Ý Q&A
´Þ¶ó½ºÀÔ´Ï´Ù. + 1
ÇÕ°Ý ÃàÇϵ帳´Ï´Ù.
±â»Û ¼Ò½Ä ÀüÇØ µå¸³´Ï´Ù.
[´äº¯] ½ÃÇè Ä¡°í ¿Ô½À´Ï´Ù.
½ÃÇè Ä¡°í ¿Ô½À´Ï´Ù.
[´äº¯] ½ÃÇè ³¯Â¥±îÁö µü ÀÏÁÖÀÏ ³²¾Ò½À´Ï´Ù.
½ÃÇè ³¯Â¥±îÁö µü ÀÏÁÖÀÏ ³²¾Ò½À´Ï´Ù.
[´äº¯] Ischemic heart disease¿¡ °üÇØ Áú¹® ÀÖ½À´Ï´Ù.
Ischemic heart disease¿¡ °üÇØ Áú¹® ÀÖ½À´Ï´Ù.
±Ã±ÝÇØ¼­ Áú¹® ¿Ã¸³´Ï´Ù... + 1